Cormedix Inc (CRMD) Reports Increased Operating Expenses Amid Pre-Launch Activities for DefenCath
-
Net Loss: Q4 net loss of $14.8 million, full-year net loss of $46.3 million.
-
Earnings Per Share (EPS): Q4 loss of $0.26 per share, full-year loss of $0.91 per share.
-
Operating Expenses: Increased by approximately $7.3 million in Q4 and $18.3 million for the full year.
-
Cash Position: $76.0 million in cash, cash equivalents, and short-term investments as of December 31, 2023.
-
Commercial Launch: DefenCath set for inpatient launch in April 2024 and outpatient in July 2024.
On March 12, 2024, Cormedix Inc (NASDAQ:CRMD) released its 8-K filing, detailing the financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, with a primary focus on its lead product candidate, DefenCath, for potential commercialization in the United States and other key markets.
The company reported a net loss of $14.8 million, or $0.26 per share, for the fourth quarter of 2023, compared to a net loss of $8.2 million, or $0.20 per share, for the same period in 2022. The full-year net loss widened to $46.3 million, or $0.91 per share, from $29.7 million, or $0.74 per share, in the previous year. The increased net loss was primarily due to higher operating expenses related to market research studies, pre-launch activities for DefenCath, and personnel expenses due to new hires.
Financial Performance and Challenges
Operating expenses for the fourth quarter surged to $15.7 million from $8.4 million in the prior-year period, an increase of approximately $7.3 million. The full-year operating expenses climbed to $49.0 million from $30.7 million in 2022, marking a 60% rise. This was attributed to a 79% increase in Selling, General, and Administrative (SG&A) expenses and a 23% increase in Research & Development (R&D) expenses.
The company's financial achievements include a robust cash position, with $76.0 million in cash, cash equivalents, and short-term investments, excluding restricted cash of $0.2 million. Cormedix believes it has sufficient resources to fund operations for at least twelve months from the issuance of its Annual Report on Form 10-K. This strong liquidity is crucial for the company as it prepares for the commercial launch of DefenCath, which is expected to begin in inpatient settings in April 2024 and in outpatient settings in July 2024.
Key Financial Metrics
Important metrics from the financial statements include: